Characteristics of 15 children treated with GO on compassionate use basis
| No. of patients | 15 |
| Age | |
| At initial diagnosis, y, median (range) | 7.9 (0.2-16.5) |
| At GO treatment, y, median (range) | 8.9 (0.7-17.3) |
| FAB classification, no. of patients | |
| M0 | 4 |
| M2 | 5 |
| M5 | 2 |
| M7 | 3 |
| AUL | 1 |
| Sex, no. of patients | |
| Male | 8 |
| Female | 7 |
| WBC count | |
| At initial diagnosis (109/L), median (range) | 20.5 (2.7-178.4) |
| At GO treatment (109/L), median (range) | 2.4 (0.1-20.0) |
| CD33 expression on blasts directly preceding GO treatment, median, % (range) | 90 (27-98) |
| Treatment protocol at initial diagnosis, no. of patients | |
| AML-BFM 93 | 3 |
| AML-BFM 98 | 9 |
| MRC12/DCLSG97 | 2 |
| NOPHO-AML 93 protocol | 1 |
| No. of patients | 15 |
| Age | |
| At initial diagnosis, y, median (range) | 7.9 (0.2-16.5) |
| At GO treatment, y, median (range) | 8.9 (0.7-17.3) |
| FAB classification, no. of patients | |
| M0 | 4 |
| M2 | 5 |
| M5 | 2 |
| M7 | 3 |
| AUL | 1 |
| Sex, no. of patients | |
| Male | 8 |
| Female | 7 |
| WBC count | |
| At initial diagnosis (109/L), median (range) | 20.5 (2.7-178.4) |
| At GO treatment (109/L), median (range) | 2.4 (0.1-20.0) |
| CD33 expression on blasts directly preceding GO treatment, median, % (range) | 90 (27-98) |
| Treatment protocol at initial diagnosis, no. of patients | |
| AML-BFM 93 | 3 |
| AML-BFM 98 | 9 |
| MRC12/DCLSG97 | 2 |
| NOPHO-AML 93 protocol | 1 |
Four patients had refractory de novo AML, 7 had refractory first relapse and 4 had second or greater relapse. Data at diagnosis and at the time point of treatment with GO are shown. FAB indicates French-American-British classification; WBC, white blood cell; AUL, acute undifferentiated leukemia.